In our study, both HER2-positive tumors demonstrated high tumor-background contrast; however, significantly higher uptake was observed in the orthotopic tumors compared to the ectopic tumors, possibly due to the microenvironment which favors tracer uptake in orthotopic tumors [48, 49]. The gene discussed is ERBB2; the disease is neoplasm.